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Abstract 
The World Health Organization (WHO) has played a key role for over 50 years in establishing the international biological 
reference preparations necessary to standardize vaccines and other biological substances as well as developing WHO guidelines 
and recommendations (written standards) on the production, control, nonclinical and clinical evaluation of biological products. 
These norms and standards, based on scientific consensus achieved through international consultations, assist WHO Member 
States in ensuring the quality, efficacy and safety of biological medicines and related in vitro biological diagnostic tests 
worldwide. The Organization accomplishes this work through the WHO Collaborating Centres and the WHO Expert Committee 
on Biological Standardization. This also involves collaboration with the international scientific and professional communities, 
regional and national regulatory authorities, manufacturers and expert laboratories worldwide. Through these activities, WHO 
has supported the concept of replacement, reduction and refinement in use of animals for developing, producing, testing and 
characterizing vaccines for human use. WHO has implemented the 3Rs principles by their adoption in certain WHO written 
standards (e.g. nonclinical evaluation, lot release), establishing well-characterized cell banks (e.g. Vero, MRC-5) that allow 
replacing primary animal cells for vaccine production, and coordinating international collaborative studies on the suitability of 
reference standards and reagents. WHO also updates written standards for vaccines based on available state-of-art knowledge and 
scientific evidence. The concept of consistency of production has been introduced for final lot release testing for a number of 
vaccines in WHO written standards and implementation of the concept has the potential to reduce animal use worldwide. The 
recently developed WHO guidelines on independent vaccine lot release encourage the national control laboratories to (1) apply 
3Rs principles to minimize the use of animals and (2) to pursue mutual recognition or collaborative agreement to accept animal 
testing performed in the exporting country's national control laboratory. 
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1. Introduction 
WHO has played a key role for over 50 years in establishing international biological reference preparations 
(IBRP) necessary to standardize vaccines and other biological substances as well as developing and updating WHO 
guidelines and recommendations (hereafter both types of technical documents are referred as "written standards") on 
the production, control, nonclinical and clinical evaluation of biological products. These norms and standards, based 
on scientific consensus achieved through international consultations, assist WHO Member States in ensuring the 
quality, efficacy and safety of biological medicines and related in vitro biological diagnostic tests worldwide. The 
Organization accomplishes this work through its biological program, the WHO Collaborating Centres, and the WHO 
Expert Committee on Biological Standardization (ECBS). This involves close collaboration with the international 
scientific and professional communities, regional and national regulatory authorities, manufacturers and expert 
laboratories worldwide. 
Reference preparations are required to standardize potency, purity, or identity measurements for complex 
biological materials. WHO IBRPs include vaccines, biotherapeutics (e.g. cytokines, hormones, growth factors and 
blood components), blood products, and in vitro diagnostics (e.g. antibodies, nucleic acids). The WHO IBRPs 
provide a global standard against which experimental values can be compared and expressed, thereby allowing 
direct comparisons between products or between measurements across different methodologies and assays in use 
around the world. To date, more than 250 IBRPs have been established; detailed information is available at 
http://www.who.int/biologicals/reference_preparations. 
Written standards describe procedures for the manufacture and quality control testing of biological medicinal 
products to ensure safe and effective products. Detailed information on WHO written standards for vaccines is 
available at: http://www.who.int/biologicals/publications/trs/areas/vaccines/en/index.html. In the context of the 
biological program at WHO, guidelines provide more general information on a range of topics of interest to national 
regulatory authorities (NRAs) and manufacturers, whereas recommendations (formerly called as "requirements") 
establish the technical specifications for manufacturing and quality control of specific products. By adopting these 
written standards in their pharmacopoeias and/or equivalent legislation, NRAs ensure that the products produced 
and used in their country are of assured quality. WHO written standards also advise NRAs and manufacturers on the 
manufacture and quality control of biological products, with the aim of establishing a harmonized regulatory 
framework for products moving in international markets. In addition, these written standards serve as the standard 
for evaluating the acceptability of vaccines for supply to countries through international agencies.  
WHO supports the concept of replacement, reduction and refinement in the use of animals (the Principles of the 
3Rs) with respect to developing, producing, testing and characterizing vaccines for human use through its program 
of biological standardization. WHO's approach to animal testing for product development including vaccine potency 
and safety testing is science-driven and program-needs-driven. WHO responds to needs of 193 Member States. As 
mandated by the Member States, WHO establishes international standards to assure the quality and safety of 
vaccines and biologicals. WHO seeks to ensure the appropriate use of animals in assuring the quality and safety of 
vaccines and biologicals. These are achieved by: (1) adopting 3Rs principles in WHO written standards on general 
topics such as guidelines for nonclinical evaluation, guidelines for lot release and in WHO written standards specific 
for each vaccine; (2) coordinating international collaborative studies on the suitability of reference standards and 
reagents for their establishment; and (3) establishing well-characterized cell banks (e.g. Vero, MRC-5) that allow 
replacing primary animal cells for vaccine production [1]. 
2. Neurovirulence safety tests 
The testing of live attenuated viral vaccines for neurovirulence has been a requirement of many regulatory 
authorities since the endorsement by WHO in 1958 (yellow fever vaccine) and 1962 (oral polio vaccine). The 
rationale was originally based on the need to test viruses with known neurovirulent properties, such as poliomyelitis 
virus and yellow fever (YF) virus. The neurovirulence tests for these viruses are based on detailed knowledge of 
their neurotropic behaviour. The polio and YF neurovirulence tests vary substantially from each other, reflecting 
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known differences in neurotropism). In some cases, there is proven value in the neurovirulence test (NVT), for 
example for oral polio vaccine for which the test is part of routine batch release procedures. Issues of neurovirulence 
tests for live viral vaccines were discussed in a meeting held by the International Association for Biologicals in 2005 
to obtain an international consensus on the need for neurovirulence testing of live viral vaccine. As a 
recommendation, the consultation group agreed that the use of other animal and non-animal models as alternatives 
to nonhuman primates needed to be encouraged and validated [2]. 
2.1.  Neurovirulence test for oral polio vaccine 
There have been significant advances in the application of alternative tests for assessing polio neurovirulence. A 
test based on a transgenic (Tg) mouse model has been validated for polio vaccine and the test was introduced as 
alternative to the monkey NVT [3]. A molecular approach involving mutant analysis by PCR and restriction enzyme 
cleavage (MAPREC assay), which complements animal tests in predicting neurovirulence, has been fully validated 
and is in routine use for type 3 poliovirus vaccines [3]. Studies on the MAPREC assay for poliovirus types 1 and 2 
vaccines are in progress. The assay has been shown to be a suitable test for poliovirus type 2, however no pass or 
fail criteria based on the proportion of mutants have been established and the assay for type 1 is at an advanced stage 
of evaluation for its suitability. Future challenges to polio NVT testing in a changing environment include: (1) 
determining whether there is a need for independent testing by NRA in the Tg mouse test; (2) maintenance of 
competence for NVT testing as polio nears eradication and after eradication; and (3) whether there is a need for 
NVT to control Sabin-IPV. In the future, it will be useful to monitor whether Tg mice will be considered as fully 
equivalent to the monkey NVT. In addition, it will be intriguing to see whether non-radioisotope MAPREC assay 
[4], or a more sophisticated DNA mass array platform based on matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry [5, 6] or microarray hybridization [7, 8] can replace the current MAPREC 
assay [9]. Apart from a site-specific mutational analysis, there may be a need for a method to look at the entire 
genome such as massively parallel sequencing to be able to detect mutational heterogeneities covering the total 
genome length [10, 11]. 
2.2.  Neurovirulence tests for live viral vaccines other than oral polio vaccine  
In the case of measles, mumps, rubella, YF and small pox vaccines, WHO recommends NVT at the level of 
vaccine virus seeds [12-14]. The purpose of neurovirulence testing at the seed level is to demonstrate that attenuated 
virus seeds used in the manufacture of vaccine lack the neurovirulence properties of wild type virus strains. Changes 
in testing procedures and evaluation criteria have been introduced to NVT for YF vaccine [15, 16]. However, 
significant effort has not been made towards the use of animal models as alternatives to nonhuman primates to date 
except mumps vaccine (see section 4.3).  
In the case of new live vaccines under clinical development, WHO guidelines on nonclinical evaluation of 
vaccines state that the need for a neurovirulence test should be based on evidence either that the natural infection is 
neurotropic or that selection for neurotropism could have occurred during the passage history of the vaccine 
candidates [17]. For example, this may occur if the attenuation process involved passage through central nervous 
system (CNS) tissue. Furthermore, one can expect that, if a neurovirulence test is indicated, that any test specified is 
able to distinguish reliably between acceptable and unacceptable preparations. This principle has been applied to 
new WHO guidelines for candidate live attenuated dengue vaccines [18]. Since dengue viruses are not regarded as 
encephalitic, a neurovirulence test for each batch is not justified, nor is there a need to test each working seed. 
However, to illustrate the complexity of providing general guidance that fits all situations, some dengue candidate 
vaccines are being developed as chimeras where one component of the chimera is derived from a virus with 
neurovirulence potential, such as dengue-yellow fever constructs [19]. In this case neurovirulence testing is required 
[18]. Acceptability of an NVT in a mouse model alternative versus NVT in non-human primates is still under 
discussion [20]. 
3. Lot release potency tests 
3.1. Potency tests for diphtheria (D), tetanus (T), pertussis (P) and combined vaccines  
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In an addendum to WHO recommendations for potency of diphtheria, tetanus, pertussis and combined vaccines 
[21], WHO recommended reduction of animal testing for the lot release of DTP vaccines. The addendum introduces 
the possibility to use (i) serological assays or (ii) challenge assay with a single dilution, both involving reduced 
number of animals, as an approach for lot release on the condition that consistency of production has been 
confirmed to the NRA/NCL on a continuous basis. The introduction of one of the alternative assaysrequires 
validation for production consistency and for an alternative assay, e.g. about 10 recent batches of vaccine are tested 
for potency by the full three-dilution challenge assay in parallel with the alternative assay. If potency expressed in 
International Unit (IU) is relatively uniform and if the expectations of linearity and parallelism are consistently 
satisfied, then fewer doses may be used and the assumptions of linearity and parallelism need not be tested in each 
assay [21].  
In revised recommendations for whole cell pertussis vaccines WHO encourages manufacturers and national 
control laboratories to use validated humane end points in recording results of potency testing that is currently based 
on death and survival of animals [22].  
3.2. Potency test for rabies vaccine 
The National Institute of Health (NIH) rabies vaccine potency test, based on a mouse protection assay with multi-
dilution doses of vaccine suspension, has long been recognized as a reliable assay for testing potency of rabies 
vaccine [23]. WHO recommends the use of validated humane end points in recording results of potency testing for 
rabies vaccines and makes it possible to use a single dilution assay for the NIH potency test [24]. The WHO 
Recommendations for rabies vaccine include that there is no additional value in performing an accelerated stability 
test for the purpose of lot release. Since this test is based on the NIH test for potency after exposure to the elevated 
temperature, this statement led to discontinuation of this test on a lot-to-lot basis in a number of countries, resulting 
in significant reduction of the number of animals. 
3.3. Potency test for YF vaccine 
Cell-culture-based infectivity unit (e.g. plaque forming units) equivalent to median mouse lethal dose was 
introduced in the amended WHO recommendations for YF vaccine potency assay [12], and in 2008, the IU of YF 
vaccine potency was defined and agreed based on international collaborative studies on the suitability of a WHO 
IBRP for YF potency [15, 16, 25]. This is in line with a previous finding reported in 1983 that the use of a common 
preparation improved the reproducibility of the results of potency testing between participating laboratories [26]. 
Results similar to this initial finding were obtained in a study carried out by Ferguson et al [25] and eventually led to 
the qualification and standardization of cell culture assays in place of the mouse potency assay with improved inter-
laboratory comparison.  
4. Current initiatives 
4.1. Cell substrate 
Revision of requirements for cell substrates is ongoing and WHO ECBS discussed the revision in October 2010 
[27]. The revision considered specific and nonspecific molecular methods such as meta-genomics approach [10] as 
complementary to a battery of animal testing for microbial extraneous agents [27]. 
4.2. Lot release 
WHO ECBS reviewed and adopted newly developed WHO guidelines on independent vaccine lot release by 
regulatory authorities in October 2010 [28]. In the guidelines WHO encourages the national control laboratories 
(NCLs) to apply 3Rs principles to minimize the use of animals when releasing a vaccine on to the market, and that 
this approach should be driven by the scientific need for valid relevant data. WHO recommends that mutual 
recognition or collaborative agreement between its Member States should be sought to utilize results of animal 
testing already performed by another NCL in the spirit of minimizing animal testing worldwide.  
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4.3. Mumps vaccine 
As described earlier in section 2.2, mumps vaccine is tested for neurovirulence at the vaccine seed level and the 
current method is based on the monkey NVT. However, studies suggested mumps virus neurovirulence testing 
performed in monkeys is not a reliable predictor to discriminate between strains with known differences in human 
neurovirulence [29, 30]. An international collaborative study on the assessment of rat-based mumps virus NVT 
showed promising results [31]. A further collaborative study on the validation of the rat-based method is planned 
using a repository of mumps vaccine seed strains that has been established at the National Institute for Biological 
Standards and Control in the United Kingdom to facilitate evaluation and validation of rat-based NVT alternative to 
monkey NVT. 
5. Conclusion 
In view of the WHO approach being science-driven and programme-needs-driven, questions that need further 
input to better implement 3Rs are: (1) what to do if the scientific basis of animal use alternatives (e.g. lack of 
correlation with immunogenicity) or methods with reduced use of animals (e.g. single-dilution dose assays) are not 
strong relative to in vivo methods? and (2) what to do if neither the in vitro nor the in vivo potency assay is 
sufficiently predictive for immunogenicity in humans?  
The examples for the former question would be inactivated Japanese encephalitis (JE) virus vaccines for which 
the potency is measured by a multi-dilution dose assay [32] and acellular pertussis vaccines assayed by modified 
intracerebral challenge assay (MICA) and histamine sensitization test (HIST) [33]. The example for the latter 
question would be hepatitis B vaccine. In the latter case, a consistency approach for post-license potency testing has 
been emphasized for regulatory acceptance of antigen quantification. This example may be useful but it should be 
interpreted with caution, and its applicability to other vaccines should be carefully considered prior to adoption of 
non-animal methods. Adopting and implementing a new antigen quantification method or reduced animal use will 
depend on the evolving regulatory environment in a specific NRA and it is difficult to forcefully influence at the 
global level. 
In conclusion, a range of WHO initiatives are progressing towards appropriate use of animals in ensuring quality 
and safety of vaccines. The WHO approach is to build evidence for new regulations through collaborative studies 
and provision of reagents to facilitate evaluation of alternatives. 
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